Inactivation of RIP3 kinase sensitizes to 15LOX/PEBP1-mediated ferroptotic death

Regulated necrosis 0301 basic medicine Medicine (General) Cell Death QH301-705.5 Ferroptotic death Lipid signaling Apoptosis Mice Necrosis 03 medical and health sciences Traumatic brain injury R5-920 Whole body irradiation Receptor-Interacting Protein Serine-Threonine Kinases Animals Ferroptosis Necroptotic death Biology (General) Oxidation-Reduction Research Paper
DOI: 10.1016/j.redox.2022.102232 Publication Date: 2022-01-10T13:23:17Z
ABSTRACT
Ferroptosis and necroptosis are two pro-inflammatory cell death programs contributing to major pathologies and their inhibition has gained attention to treat a wide range of disease states. Necroptosis relies on activation of RIP1 and RIP3 kinases. Ferroptosis is triggered by oxidation of polyunsaturated phosphatidylethanolamines (PUFA-PE) by complexes of 15-Lipoxygenase (15LOX) with phosphatidylethanolamine-binding protein 1 (PEBP1). The latter, also known as RAF kinase inhibitory protein, displays promiscuity towards multiple proteins. In this study we show that RIP3 K51A kinase inactive mice have increased ferroptotic burden and worse outcome after irradiation and brain trauma rescued by anti-ferroptotic compounds Liproxstatin-1 and Ferrostatin 16-86. Given structural homology between RAF and RIP3, we hypothesized that PEBP1 acts as a necroptosis-to-ferroptosis switch interacting with either RIP3 or 15LOX. Using genetic, biochemical, redox lipidomics and computational approaches, we uncovered that PEBP1 complexes with RIP3 and inhibits necroptosis. Elevated expression combined with higher affinity enables 15LOX to pilfer PEBP1 from RIP3, thereby promoting PUFA-PE oxidation and ferroptosis which sensitizes Rip3K51A/K51A kinase-deficient mice to total body irradiation and brain trauma. This newly unearthed PEBP1/15LOX-driven mechanism, along with previously established switch between necroptosis and apoptosis, can serve multiple and diverse cell death regulatory functions across various human disease states.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (57)
CITATIONS (29)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....